Abstract
purpose. Inhibition of TGF-β reduces myofibroblast differentiation and fibrosis in the cornea. Determining the actions of distinct TGF-β isoforms and their inhibitors during early corneal wound healing is an essential step in guiding therapeutic intervention.
methods. Bovine serum-free corneal cell and wounded organ cultures were challenged with a range of concentrations of TGF-β1, -β2, and -β3; IL-10; and neutralizing human monoclonal antibodies (mAbs) against TGF-β1 (CAT-192) or -β2, (CAT-152). Cultures were assessed for re-epithelialization, proliferation (cell counts and cresyl violet assay), morphology (histologic examination), repopulation of the area under the wound, and myofibroblast transformation (α-smooth muscle actin) between 0 and 5 days.
results. TGF-β1 delayed re-epithelialization, increased repopulation of the stroma, increased keratocyte proliferation and was the only isoform to promote myofibroblast differentiation. The anti-TGF-β1 mAb, CAT-192 promoted re-epithelialization and reduced repopulation of the stroma. Exogenous TGF-β3 had little effect on re-epithelialization but reduced repopulation of the stroma. IL-10 promoted corneal re-epithelialization at low doses but inhibited this response at high doses. Stromal repopulation was prevented by all doses of IL-10. TGF-β2 or the anti-TGF-β2 mAb, CAT-152 had little effect on any repair parameter.
conclusions. The results confirm TGF-β1 as the principal isoform in corneal wound healing and suggest that inhibition of the action of TGF-β1 can promote corneal wound healing. Treatment with the anti-TGF-β1 mAb CAT-192 accelerates corneal re-epithelialization but reduces cell repopulation of the stroma. The cytokines TGF-β3 and IL-10 have opposing actions to that of TGF-β1.
TGF-β has been established as a major regulator of wound healing in most species and tissues, including the cornea.
1 2 3 To date, TGF-β
1 and -β
2 have been localized to both the corneal epithelium and stroma, and both are constituents of the tear fluid (Vesaluoma M, et al.
IOVS 1996;37:ARVO Abstract 3912).
4 5 6 7 8 9 Although mRNA of the β
3 isoform has been isolated from whole rat corneas at very low levels, its tissue location is unclear, and the protein has yet to be detected in the nonpathologic cornea.
6 10
The TGFβ receptors RI and RII are located in epithelial, stromal, and endothelial layers of the cornea.
11 12 13 RI and RII are present predominantly in the basal layer of corneal epithelial cells, with receptor density increasing proximal to the limbus in many species, including humans. The nonsignaling TGFβ-RIII (β-glycan receptor) has been located on both the epithelium and endothelium in vivo, but appears to be absent in keratocytes in vivo.
11
As with many other growth factor signaling systems the levels and spatial location of each component in the TGF-β system alters dramatically after a corneal wound. All three isoforms are present in the corneal epithelium,
4 14 15 16 and corneal epithelial cells in culture release TGF-β
1 and -β
2.
17 18 TGF-β
2 is reported to be more strongly expressed than the other two isoforms
4 and throughout wound healing after PRK and TGF-β
1, -β
2, and -β
3 are present in the corneal epithelium.
19 In stromal cells TGF-β is upregulated,
15 but isoforms cannot be detected immunohistochemically until 2 days after PRK, when rounded cells in the ablated area express all three isoforms. TGF-β
1, -β
2, and -β
3 expression is delayed in spindle shaped fibroblasts until 10 days after PRK. Expression of all three isoforms returns to normal after 30 days. In addition, levels of TGF-β
1 in the tear film increase dramatically (Vesaluoma M, et al.
IOVS 1996;37:ARVO Abstract 3912). Of particular interest is the finding that topical administration of 1D11, a TGF-β
1-, -β
2-, and -β
3-neutralizing antibody, to rabbit corneas after PRK and lamellar keratectomy wounds, results in a reduction in the appearance of myofibroblasts, and substantially decreases the incidence of haze in rabbits.
2 3 Taken together, this indicates a pivotal role for the TGF-β system in corneal maintenance and wound repair.
The TGF-β superfamily is a structurally related group of bioactive ubiquitous proteins with diverse and pleiotropic activities. TGF-β1 and -β2 share 80% sequence homology but can have opposite actions on biological processes such as proliferation, migration, and differentiation.
1 The role of the various isoforms of TGF-β in corneal wound healing is not fully understood, and therefore optimal treatment may rely on selective inhibition of one or more TGF-β isoforms. To manipulate the cytokine environment of the healing cornea after either trauma or elective surgery, it is necessary to understand the actions of each TGF-β isoform. It appears increasingly likely that the events occurring within the earliest stages of corneal wound healing alter prognosis.
2 3 Herein, we describe the very different actions of the three TGF-β isoforms in early corneal wound-healing events and their inhibition by human isoform-specific neutralizing antibodies. The action of the cytokine IL-10, a potential antagonist of TGF-β, was also evaluated. The results of the study have been reported in part in abstract form (Carrington LM, et al.
IOVS 2001;42:ARVO Abstract 5018).
Cultured cells were fixed at 0, 1, 2, 3, 4, and 5 days after treatment in 1% paraformaldehyde for 5 minutes. Corneal organ cultures were snap frozen in liquid nitrogen at 0, 1, 2, 3, and 5 days after treatment; embedded in optimal cutting temperature compound (OCT); and sectioned at 5-μm intervals. Cultures and sections were pretreated with 0.1% Triton-X-100 for 20 minutes, incubated with a monoclonal anti-α smooth muscle actin antibody (Sigma-Aldrich) for 2 hours followed by an Alexafluor 488-conjugated goat anti-mouse IgG (Invitrogen, Eugene, OR) for 1 hour. Counterstaining of nuclei was obtained using bis-benzimide solution incubation for 10 minutes. Cell cultures were also costained with TRITC-conjugated phalloidin (5 μg/mL in PBS; Sigma-Aldrich) for 2 hours, to identify F-actin.
Keratocyte Cell Culture.
Trephine-Wounded Corneas.
We present evidence that TGF-β isoforms differentially regulate several key events in early corneal wound healing. TGF-β1 appeared to be the most active corneal isoform and was able to delay re-epithelialization, increase proliferation of keratocytes, enhance repopulation of the periwound area, and promote myofibroblast transformation. Moreover, neutralization of endogenously produced TGF-β1 after treatment with the anti-TGF-β1 mAb, CAT-192, mediated an effect opposite the response to exogenously added TGF-β1. In contrast to the TGF-β1 isoform, TGF-β3 reduced the keratocyte repopulation of the periwound area. TGF-β2 or neutralization of TGF-β2 with the selective antibody CAT-152 had little effect on corneal wound healing.
The effects of TGF-β
1 reported in this study concur with the findings of other investigators in various species. First, TGF-β
1 was the only factor capable of inducing α-smooth muscle actin expression in stromal cells in cell and organ culture, a well-documented phenomenon.
3 22 Second, TGF-β
1 increased the number of cells under the wound in wounded, organ-cultured corneas, a finding in common with reports in the literature involving rabbits.
3 Third, a neutralizing antibody against the active form of TGF-β
1, inhibits the slow repopulation of stromal cells under the wound as previously shown after laser keratectomy.
23 Although not examined in this study, it is likely that these events are, at least in part, mediated via connective tissue growth factor.
24
TGF-β
3 inhibited not only the repopulation of the stroma observed in the control but also decreased the number of cells below that seen at any time point in untreated corneas. Of note, neutralizing TGF-β
3 had no effect, either on the number of cells beneath the wound or the expression of laminin and fibronectin in the cornea,
23 and thus may act by inhibiting the action of endogenous TGF-β
1 as occurs during wound healing in the skin.
25 TGF-β
3 knockout mice demonstrate scarring in the fetal stage that does not occur after wounding in the wild-type equivalent,
26 and it appears that the ratio of TGF-β
1 to -β
3 is critical in determining the extent of fibrosis. Thus, TGF-β
3 may be a candidate for therapeutic interventions, especially because it had no detrimental effect on corneal re-epithelialization in this study.
Møller-Pedersen et al.
2 have reported that a pan neutralizing antibody (1D11) able to block all isoforms of TGFβ reduced keratocyte activation and transformation and inhibited stromal fibrosis in a rabbit model of PRK. However, in this rabbit model, the regrowth of the stroma was unaffected by pan isoform neutralization with 1D11. Our results suggest that while neutralizing TGF-β
1 may be important in preventing fibrosis, the neutralization of TGF-β
3 may well be agonistic to TGF-β
1 action. One may postulate that the best outcome (of a single agent) would be selective neutralization of TGF-β
1, and this could be achieved with the human monoclonal antibody CAT-192. This approach may reduce fibrosis, keratocyte transformation (and hence light-reflective keratocytes), as well as repopulation of the stroma. Rapid re-epithelialization would also limit additional stromal trauma. This approach would be worthy of study in a model system such as experimental PRK.
IL-10 is classically regarded as a potent anti-inflammatory cytokine and most studies into its function and effect have centered on this premise. This study is the first to report the effect of IL-10 on corneal wound healing. IL-10 was seen to have a pleiotropic effect on the epithelium, increasing re-epithelialization at 10 ng/mL, but suppressing wound coverage at 100 ng/mL.
Sources for IL-10 include TH
2 cells
27 and monocytes,
28 both of which should have no access to the cornea in nonpathologic situations. IL-10 mRNA has been isolated from the corneas of mice both before and after alkali burns
29 and in humans during corneal transplant surgery.
30 Corneal epithelial cells are a likely candidate, as the epithelia of other organs including skin produce IL-10.
31 32 33 Previous studies have shown that IL-10 treatment can reduce the migration of T-cells and neutrophils into HSV-1-infected mouse corneas,
34 reduce HLA-DR expression on corneal cells and infiltrating leukocytes of human herpetic stromal keratitis specimens,
35 and decrease corneal opacification in HSV-1-infected BALB/c mice.
34 36 All of these in vivo experiments were performed in the presence of a functioning immune system and were characterized by immune cell infiltration of the cornea, which could have mediated the effects of IL-10 on the corneal cells. The current study is therefore the first to show that corneal cells, in the absence of lymphocytes, can respond to IL-10 treatment and as such provides compelling evidence that the cornea contains the IL-10 receptor. Indeed, the upregulation of IL-10 Rc mRNA expression has been identified in corneas after excimer laser injury.
37
Little is known about the mechanism by which IL-10 regulates epithelial cells and fibroblasts. IL-10 has been shown to have antagonistic effects to the actions of TGF-β,
38 although how this is achieved is unclear. IL-10 has been shown to modulate extracellular matrix components by downregulating type I collagen expression and upregulating collagenase and stomelysin mRNA in human skin fibroblasts
39 ; reducing constitutive and transforming growth factor-β-stimulated, type I collagen mRNA expression in human lung fibroblast cells
40 ; and downregulating the biosynthesis of fibrinogen in smooth muscle cells,
41 all of which may contribute to modulation of fibrosis.
Our study confirms the primary role of the β1 isoform of TGF during corneal wound healing. Furthermore, it identifies IL-10 and TGF-β3 as potential therapeutic regulators of corneal repair and the prevention of fibrosis. It is also likely that early application of treatment will be essential to minimize adverse healing and optimize repair. A postoperative indication such as corneal refractive surgery could be benefited by this type of biological therapy.
Presented in part at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 2001.
Supported by the Wellcome Trust, BBSRC, the Guide Dogs for the Blind Association, and Cambridge Antibody Technology.
Submitted for publication May 22, 2005; revised November 12, 2005, and January 4, 2006; accepted March 17, 2006.
Disclosure:
L. M. Carrington, Cambridge Antibody Technology (F);
J. Albon, None;
I. Anderson, Cambridge Antibody Technology (E);
C. Kamma, None;
M. Boulto n, Cambridge Antibody Technology (F)
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “
advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Mike Boulton, School of Optometry and Vision Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF103NB, UK;
[email protected].
O’KaneS, FergusonM. Transforming growth factor betas and wound healing. Int J Biochem Cell Biol. 1997;29:63–78.
[CrossRef] [PubMed]Møller-PedersenT, CavanaghH, PetrollW, JesterJ. Neutralising antibody to TGF-beta modulates stromal fibrosis but not regression of photoablative effect following PRK. Curr Eye Res. 1998;17:736–747.
[CrossRef] [PubMed]JesterJV, BarryLanePA, PetrollWM, OlsenDR, CavanaghHD. Inhibition of corneal fibrosis by topical application of blocking antibodies to TGF(beta) in the rabbit. Cornea. 1997;16:177–187.
[PubMed]NishidaK, KinoshitaS, YokoiN, et al. Immunohistochemical localization of transforming growth factor-beta-1, factor-beta-2, and factor-beta-3 latency-associated peptide in human cornea. Invest Ophthalmol Vis Sci. 1994;35:3289–3294.
[PubMed]NishidaK, SotozonoC, AdachiW, YamamotoS, YokoiN, KinoshitaS. Transforming growth factor β1, -β2 and -β3 mRNA expression in human cornea. Curr Eye Res. 1995;14:235–241.
[CrossRef] [PubMed]PasqualeLR, Dorman-PeaseME, LuttyGA, et al. Immunolocalization of Tgf-beta-1, Tgf-beta-2, and Tgf-beta-3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci. 1993;34:23–30.
[PubMed]AbrahamianA, XiMS, DonnellyJJ, RockeyJH. Effect of interferon-gamma on the expression of transforming growth-factor-beta by human corneal fibroblasts: role in corneal immunoseclusion. J Interferon Cytokine Res. 1995;15:323–330.
[CrossRef] [PubMed]ChenKH, HarrisDL, JoyceNC. TGF-beta 2 in aqueous humor suppresses S-phase entry in cultured corneal endothelial cells. Invest Ophthalmol Vis Sci. 1999;40:2513–2519.
[PubMed]GuptaA, MonroyD, JiZ, YoshinoK, HuangA, PflugfelderS. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res. 1996;15:605–614.
[CrossRef] [PubMed]ChenC, Michelini-NorrisB, StevensS, et al. Measurement of mRNAs for TGF beta and extracellular matrix proteins in corneas of rats after PRK. Invest Ophthalmol Vis Sci. 2000;41:4108–4116.
[PubMed]JoyceN, ZieskeJ. Transforming growth factor beta-receptor expression in the human cornea. Invest Ophthalmol Vis Sci. 1997;38:1922–1928.
[PubMed]ObataH, KaburakiT, KatoM, YamashitaH. Expression of TGF-beta type I and type II receptors in rat eyes. Curr Eye Res. 1996;15:335–340.
[CrossRef] [PubMed]ObataH, KajiY, YamadaH, KatoM, TsuruT, YamashitaH. Expression of transforming growth factor-beta superfamily receptors in rat eyes. Acta Ophthalmol Scand. 1999;77:151–156.
[CrossRef] [PubMed]WilsonS, HeY, LloydS. EGF, EGF receptor, basic FGF, TGF beta-1, and IL-1 alpha mRNA in human corneal epithelial cells and stromal fibroblasts. Invest Ophthalmol Vis Sci. 1992;33:1756–1765.
[PubMed]HayashiGF, WolfG, KenyonK. Expression of transforming growth factor-beta in wound healing of vitamin A-deficient rat corneas. Invest Ophthalmol Vis Sci. 1989;30:239–247.
[PubMed]MitaT, YamashitaH, KajiY, et al. Effects of transforming growth factor beta on corneal epithelial and stromal function in a rat wound healing model. Graefes Arch Clin Exp Ophthalmol. 1998;236:834–843.
[CrossRef] [PubMed]StrissellK, RinehartW, FiniM. A corneal epithelial inhibitor of stromal cell collagenase synthesis identified as TGFβ2. Invest Ophthalmol Vis Sci. 1995;36:151–162.
[PubMed]PancholiS, TulloA, KhaliqA, ForemanD, BoultonM. The effects of growth factors and conditioned media on the proliferation of human corneal epithelial cells and keratocytes. Graefes Arch Clin Exp Ophthalmol. 1998;235:1–8.
KajiY, MitaT, ObataH, et al. Expression of transforming growth factor beta superfamily and their receptors in the corneal stromal wound healing process after excimer laser keratectomy. Br J Ophthalmol. 1998;82:462–463.
[PubMed]CarringtonL, BoultonM. HGF and KGF regulate both epithelial and stromal corneal wound healing. J Cataract Refract Surg. 2005;31:412–423.
[CrossRef] [PubMed]ForemanD, PancholiD, Jarvis-EvansJ, McLeodD, BoultonM. A simple organ culture model for assessing the effects of growth factors on corneal reepithelialisation. Exp Eye Res. 1996;62:555–564.
[CrossRef] [PubMed]JesterJ, BarryP, CavanaghM, PetrollW. Induction of alpha smooth muscle actin expression and myofibroblast transformation in cultured corneal keratocytes. Cornea. 1996;115:505–516.
MitaT, YamashitaH, KajiY, et al. Functional difference of TGF-beta isoforms regulating corneal wound healing after excimer laser keratectomy. Exp Eye Res. 1999;68:513–519.
[CrossRef] [PubMed]BlomIE, van DijkAJ, WietenL, et al. In vitro evidence for differential involvement of CTGF, TGF beta, and PDGF-BB in mesangial response to injury. Nephrol Dialysis Transplant. 2001;16:1139–1148.
[CrossRef] ShahM, ForemanD, FergusonM. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995;108:985–1002.
[PubMed]CowinAJ, HolmesTM, BrosnanP, FergusonMW. Expression of TGF-beta and its receptors in murine fetal and adult dermal wounds. Eur J Dermatol. 2001;11:424–431.
[PubMed]FiorentinoDF, BondMW, MosmannTR. Two types of mouse T helper cell IV Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170:2081–2095.
[CrossRef] [PubMed]SerotJM, BeneMC, FoliguetB, FaureGC. Monocyte-derived IL-10-secreting dendritic cells in choroid plexus epithelium. J Neuroimmunol. 2000;105:115–119.
[CrossRef] [PubMed]SotozonoC, HeJC, MatsumotoY, KitaM, ImanishiJ, KinoshitaS. Cytokine expression in the alkali-burned cornea. Curr Eye Res. 1997;16:670–676.
[CrossRef] [PubMed]KingWJ, ComerRM, HuddeT, LarkinDF, GeorgeAJ. Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation. 2000;70:1225–1233.
[CrossRef] [PubMed]EnkAH, KatzSI. Identification and induction of keratinocyte-derived Il-10. J Immunol. 1992;149:92–95.
[PubMed]DosanjhA, MorrisRE, WanB. Bronchial epithelial cell-derived cytokine IL-10 and lung fibroblast proliferation. Transplant Proc. 2001;33:352–354.
[CrossRef] [PubMed]YoshidaM, TakeuchiM, StreileinJW, et al. Participation of pigment epithelium of iris and ciliary body in ocular immune privilege. 1. Inhibition of T-cell activation in vitro by direct cell-to-cell contact. Invest Ophthalmol Vis Sci. 2000;41:811–821.
[PubMed]TumpeyTM, ChengH, YanXT, OakesJE, LauschRN. Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-l0. J Leukocyte Biol. 1998;63:486–492.
[PubMed]BoorsteinSM, ElnerSG, MeyerRF, et al. Interleukin-10 Inhibition of HLA-DR expression in human herpes stromal keratitis. Ophthalmology. 1994;101:1529–1535.
[CrossRef] [PubMed]MinagawaH, SakaiY, LiY, IshibashiT, InomataH, MoriR. Suppression of infectious virus spread and corneal opacification by the combined use of recombinant interferon beta and interleukin-10 following corneal infection with herpes simplex virus-1 in mice. Antiviral Res. 1997;36:99–105.
[CrossRef] [PubMed]CaoZ, WuHK, BruceA, WollenbergK, PanjwaniN. Detection of differentially expressed genes in healing mouse corneas, using cDNA microarrays. Invest Ophthalmol Vis Sci. 2002;43:2897–2904.
[PubMed]CarringtonL, McLeodD, BoultonM. IL-10 and antibodies to TGF-beta(2) and PDGF inhibit RPE-mediated retinal contraction. Invest Ophthalmol Vis Sci. 2000;41:1210–1216.
[PubMed]ReitamoS, RemitzA, TamaiK, UittoJ. Interleukin-10 modulates type I collagen and matrix metalloproteinase gene expression in cultured human skin fibroblasts. J Clin Invest. 1994;94:2489–2492.
[CrossRef] [PubMed]AraiT, AbeK, MatsuokaH, et al. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol. 2000;278:L914–L922.
[PubMed]VasseM, PaysantI, SoriaJ, MirshahiSS, VannierJP, SoriaC. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol. 1996;93:955–961.
[CrossRef] [PubMed]